Abscopal effect in a patient with malignant pleural mesothelioma treated with palliative radiotherapy and pembrolizumab.

Détails

Ressource 1Télécharger: 33532635.pdf (1770.75 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY-NC-ND 4.0
ID Serval
serval:BIB_C82F89BA6EDB
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Institution
Titre
Abscopal effect in a patient with malignant pleural mesothelioma treated with palliative radiotherapy and pembrolizumab.
Périodique
Clinical and translational radiation oncology
Auteur(s)
Mampuya W.A., Bouchaab H., Schaefer N., Kinj R., La Rosa S., Letovanec I., Ozsahin M., Bourhis J., Coukos G., Peters S., Herrera F.G.
ISSN
2405-6308 (Electronic)
ISSN-L
2405-6308
Statut éditorial
Publié
Date de publication
03/2021
Peer-reviewed
Oui
Volume
27
Pages
85-88
Langue
anglais
Notes
Publication types: Case Reports
Publication Status: epublish
Résumé
The abscopal effect describes the ability of locally administered radiotherapy to induce systemic antitumor effects. Although mentioned for the first time in the 1950s, records of abscopal effects, considered to be immune-mediated, are scarce with radiotherapy alone. However, with the continued development and use of immunotherapy, reports on the abscopal effect have become increasingly frequent during the last decade. Here, we report a patient with advanced malignant pleural mesothelioma who had progressive disease while on the anti-PDL1 inhibitor pembrolizumab and showed an abscopal response after palliative radiotherapy.
Mots-clé
Abscopal effect, Checkpoint inhibitors, Immunotherapy, Malignant pleural mesothelioma, Radiotherapy
Pubmed
Web of science
Open Access
Oui
Création de la notice
01/02/2021 19:02
Dernière modification de la notice
23/08/2021 15:44
Données d'usage